**US5324571083 - Common Stock - Premarket: 335.8 -6.77 (-1.98%)**

Overall **LLY** gets a fundamental rating of **5** out of 10. We evaluated **LLY** against 261 industry peers in the **Pharmaceuticals** industry. While **LLY** has a great profitability rating, there are some minor concerns on its financial health. While showing a medium growth rate, **LLY** is valued expensive at the moment.

ROA (12.71%) VS Industry: 60% outperformed.

0.97

111.39

ROE (59.91%) VS Industry: 85% outperformed.

1.97

178.77

Profit Margin (20.63%) VS Industry: 60% outperformed.

2.50

1,952.78

The **Price/Earnings Ratio** is **40.35**, which means the current valuation is very expensive for **LLY**.

Compared to an average industry **Price/Earning Ratio** of **13.58**, **LLY** is valued more expensive than its industry peers. On top of this 93% of the companies listed in the same industry are cheaper than **LLY**!

With a **Forward Price/Earnings Ratio** of **37.08**, **LLY** is valued very expensively.

The high **PEG Ratio**, which compensates the Price/Earnings for growth, indicates **LLY** does not grow enough to justify the current Price/Earnings ratio.

With a price book ratio of **33.58**, **LLY** is valued rather expensively.

Compared to an average industry price book ratio of 1.50, **LLY** is valued more expensive than its industry peers. **98%** of the companies listed in the same industry are valued cheaper.

When comparing the **Enterprise Value to EBITDA** ratio of **LLY** to the average industry ratio of 11.35, **LLY** is valued more expensive than its industry peers. **88%** of the companies listed in the same industry are valued cheaper.

Price/Earnings (40.35) VS Industry: 7% outperformed.

112.77

0.02

Price/Book (33.58) VS Industry: 2% outperformed.

540.61

0.13

Enterprise Value/ EBITDA (34.57) VS Industry: 12% outperformed.

258.44

0.25

Based on estimates for the next 5 years, **LLY** will show a quite strong growth in **Earnings Per Share**. The EPS will grow by **17.90%** on average per year.

When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.

When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.

The **Revenue** has been growing slightly by **5.94%** on average over the past 5 years.

Past | Future | ||||||
---|---|---|---|---|---|---|---|

5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |

EPS | 18.34% | 13.69% | 0.71% | -3.85% | 6.35% | 14.91% | 17.9% |

Revenue | 5.94% | 9.63% | 5.34% | 2.09% | 3.66% | 8.11% | 11.67% |

The Piotroski-F score of **LLY** is **8.00**. This is a very strong score and indicates great health and profitability for **LLY**.

When comparing the Current Ratio of **LLY** to the average industry Current Ratio of **3.49**, **LLY** is less able to pay its short term obligations than its industry peers. **85%** of its industry peers have a better Current Ratio.

A Quick Ratio of **0.88** indicates that **LLY** may have some problems paying its short term obligations.

When comparing the Quick Ratio of **LLY** to the average industry Current Ratio of **2.84**, **LLY** is less able to pay its short term obligations than its industry peers. **84%** of its industry peers have a better Quick Ratio.

Compared to an average industry Debt to Equity Ratio of **0.00**, **LLY** is requires more financing than its industry peers. **91%** of its industry peers have a better Debt to Equity Ratio.

Debt/Equity (1.4) VS Industry: 9% outperformed.

59.36

0.00

Quick Ratio (0.88) VS Industry: 16% outperformed.

-2.73

76.82

Current Ratio (1.13) VS Industry: 15% outperformed.

0.10

76.82

Altman-Z (6.98) VS Industry: 82% outperformed.

-244.28

84.57

The dividend of **LLY** is nicely growing with an annual growth rate of **14.75%**!

With a **Dividend Yield** of **1.31**, **LLY** pays less dividend than the industry average, which is at **2.85**. 83% of the companies listed in the same industry pay a better dividend than **LLY**!

Compared to an average S&P500 **Dividend Yield** of **2.41**, **LLY**'s dividend is way lower than the S&P500 average.

The dividend of **LLY** is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.

Dividend Yield (1.31%) VS Industry: 17% outperformed.

0.71

7.11

NYSE:LLY (2/1/2023, 7:25:37 PM)**-1.58 (-0.46%) **

GICS Sector | Health Care | ||

GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||

GICS Industry | Pharmaceuticals | ||

Earnings (Last) | 11-01 2022-11-01/bmo | Earnings (Next) | 02-02 2023-02-02 |

Inst Owners | 80.23% | Inst Owner Change | -0.1% |

Ins Owners | 10.56% | Ins Owner Change | -0.89% |

Market Cap | 338.16B | Analysts | 80 |

Price Target | 397.31 (15.98%) |

Dividend Yield | 1.31% | Dividend Growth | 14.75% |

DP | 56.76% | Ex-Date | 02-14 2023-02-14 (1.13) |

EPS beat(2) | 1 | Avg EPS beat(2) | -12.22% |

Min EPS beat(2) | -26.71% | Max EPS beat(2) | 2.27% |

EPS beat(4) | 3 | Avg EPS beat(4) | -1.52% |

Min EPS beat(4) | -26.71% | Max EPS beat(4) | 18.07% |

Revenue beat(2) | N/A | Avg Revenue beat(2) | -3.2% |

Min Revenue beat(2) | -6.12% | Max Revenue beat(2) | -0.28% |

Revenue beat(4) | 2 | Avg Revenue beat(4) | 0.21% |

Min Revenue beat(4) | -6.12% | Max Revenue beat(4) | 4.79% |

PT rev (1m) | 0.45% | PT rev (3m) | 11.54% |

EPS NQ rev (1m) | 0% | EPS NQ rev (3m) | -9.85% |

EPS NY rev (1m) | 0% | EPS NY rev (3m) | -2.25% |

Revenue NQ rev (1m) | 0% | Revenue NQ rev (3m) | -2.32% |

Revenue NY rev (1m) | 0% | Revenue NY rev (3m) | -0.5% |

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 40.35 | ||

Fwd PE | 37.08 | ||

P/S | 11.57 | ||

P/FCF | 63.34 | ||

P/OCF | 44.14 | ||

P/B | 33.58 | ||

P/tB | N/A | ||

EV/EBITDA | 34.57 |

EPS(TTM) | 8.49 | EY | 2.48% |

EPS(NY) | 9.24 | Fwd EY | 2.7% |

FCF(TTM) | 5.41 | FCFY | 1.58% |

OCF(TTM) | 7.76 | OCFY | 2.27% |

SpS | 29.62 | BVpS | 10.2 |

TBVpS | -0.96 | PEG (NY) | N/A |

PEG (5Y) | 2.2 |

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 12.71% | ||

ROE | 59.91% | ||

ROIC | 23.74% | ||

ROICexc | 25.98% | ||

ROICexgc | 41.83% | ||

OM | 29.29% | ||

PM | 20.63% | ||

GM | 75.61% |

ROICexgc(3y) | 33.07% | ROICexcg growth 3Y | 17.44% |

ROICexcg growth 5Y | 9.5% | ROICexc(3y) | 20.45% |

ROICexc growth 3Y | 3.15% | ROICexc growth 5Y | 8.56% |

OM growth 3Y | -0.33% | OM growth 5Y | 7.88% |

PM growth 3Y | 9.44% | PM growth 5Y | 8.85% |

GM growth 3Y | -1.75% | GM growth 5Y | 0.22% |

F-Score | 8 | Asset Turnover | 0.62 |

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1.4 | ||

Debt/FCF | 2.98 | ||

Debt/EBITDA | 1.56 | ||

Cap/Depr | 145.78% | ||

Profit Quality | 88.49% | ||

Current Ratio | 1.13 | ||

Quick Ratio | 0.88 | ||

Altman-Z | 6.98 |

F-Score | 8 | WACC | 8.41% |

ROIC/WACC | 4.97 | Cap/Depr(3y) | 128.04% |

Cap/Depr(5y) | 141.95% | Profit Quality(3y) | 70.19% |

Profit Quality(5y) | N/A |

EPS 1Y | 0.71% | EPS 3Y | 13.69% |

EPS 5Y | 18.34% | EPS growth Q2Q | 2.06% |

EPS Next Y | -3.85% | EPS Next 2Y | 6.35% |

EPS Next 3Y | 14.91% | EPS Next 5Y | 17.9% |

Revenue growth 1Y | 5.34% | Revenue growth 3Y | 9.63% |

Revenue growth 5Y | 5.94% | Revenue growth Q2Q | 2.49% |

Revenue Next Year | 2.09% | Revenue Next 2Y | 3.66% |

Revenue Next 3Y | 8.11% | Revenue Next 5Y | 11.67% |

EBIT growth 1Y | 14.52% | EBIT growth 3Y | 9.27% |

EBIT growth 5Y | 14.28% | EBIT Next Year | 10.09% |

EBIT Next 3Y | 19.49% | EBIT Next 5Y | 20.67% |

FCF growth 1Y | 4.43% | FCF growth 3Y | 29.06% |

FCF growth 5Y | 7.46% | OCF growth 1Y | 15.24% |

OCF growth 3Y | 9.54% | OCF growth 5Y | 8.4% |

*Find stocks with similar Fundamental rating on the USA*

*Find the competitors with the best fundamentals on the USA*

*Find the competitors with the best valuation on the USA*

*Find the competitors with the best dividend on the USA*